Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer

January 20, 2012 updated by: Incyte Corporation

A Phase I/II Study to Assess the Safety and Therapeutic Effect of INCB007839 in Combination With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer.

This Phase I/II study is designed to assess the safety and therapeutic effect of INCB007839 in combination with trastuzumab and vinorelbine in patients with metastatic HER2+ breast cancer.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

20

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arkansas
      • Fayetteville, Arkansas, United States
    • California
      • Duarte, California, United States
    • Colorado
      • Denver, Colorado, United States
    • Florida
      • Davie, Florida, United States
      • Jacksonville, Florida, United States
    • Michigan
      • Detroit, Michigan, United States
    • Missouri
      • St. Louis, Missouri, United States
    • New Jersey
      • Hackensack, New Jersey, United States
    • New York
      • Lake Success, New York, United States
    • North Carolina
      • Huntersville, North Carolina, United States
    • Ohio
      • Cincinnati, Ohio, United States
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States
    • Tennessee
      • Nashville, Tennessee, United States
    • Utah
      • Salt Lake, Utah, United States

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Subject with diagnosis of metastatic (or locally recurrent-inoperable) breast cancer
  • Subject with histological HER2+ status as determined by FISH with a gene amplification score of ≥ 2.2
  • Subject with availability of archival biopsy tissue from primary tumor or metastatic lesions
  • Subject with presence of measurable disease based on RECIST 1.1
  • Subject who has received no more than three prior HER2-directed therapeutic regimens for advanced breast cancer

Exclusion Criteria:

  • Subject with Left ventricular ejection fraction (LVEF) below institutional normal range
  • Subject with metastasis to the central nervous system UNLESS asymptomatic and clinically stable
  • Subject with current active malignancy other than breast cancer
  • Subject with prior history of other malignancy except for cancers from which the patient is currently disease free
  • Subject with significant renal or hepatic dysfunction
  • Subject with history of venous or arterial thrombosis or risk factor for thrombosis other than history of malignancy
  • Subject with insufficient bone marrow function
  • Subject with contraindication to vinorelbine, trastuzumab, aspirin and/or warfarin therapy.
  • Subject with current active bacterial, Hepatitis B or C, and/or HIV infections

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Treatment A - INCB007839 300mg BID
This is a single arm, open label study in which all patients will receive a single dose of the investigational product INCB007839 in combination with a standard regimen of trastuzumab and vinorelbine.
Drug: INCB007839 300mg BID
INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
Drug: Trastuzumab
INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
Drug: Vinorelbine
INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Evaluation of safety and tolerabilty as determined by monitoring the frequency and severity of adverse events (AEs) and performing clinical assessments and laboratory investigations.
Time Frame: Measured monthly starting at Baseline (estimated duration 6-9 months)
Measured monthly starting at Baseline (estimated duration 6-9 months)

Secondary Outcome Measures

Outcome Measure
Time Frame
Overall objective response rate assessed by RECIST criteria
Time Frame: Measured at Baseline, Cycle 4 and approximately every 9 weeks after (estimated duration 6-9 months)
Measured at Baseline, Cycle 4 and approximately every 9 weeks after (estimated duration 6-9 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Incyte Corporation

Investigators

  • Principal Investigator: Denise A. Yardley, MD, Sara Cannon Research Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2010

Primary Completion (Actual)

September 1, 2011

Study Completion (Actual)

October 1, 2011

Study Registration Dates

First Submitted

December 1, 2010

First Submitted That Met QC Criteria

December 2, 2010

First Posted (Estimate)

December 6, 2010

Study Record Updates

Last Update Posted (Estimate)

January 25, 2012

Last Update Submitted That Met QC Criteria

January 20, 2012

Last Verified

January 1, 2012

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • INCB 7839-204

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on INCB007839 300mg BID

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe